Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 8/20 | 0.52 |
| ▸ | FNTB | P49356 | 8/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17339148 | 0.81 | ALDH1A1 (0.61) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL28532373 | 0.81 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL28910370 | 0.79 | FNTA (0.50) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL17339205 | 0.77 | KDM4E (0.58) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL28540023 | 0.76 | FNTA (0.55) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL9535179 | 0.76 | KDM4E (0.69) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL28531366 | 0.76 | FNTA (0.48) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL10361678 | 0.76 | ALDH1A1 (0.81) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL28539107 | 0.76 | KDM4E (0.49) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL27211444 | 0.75 | ALDH1A1 (0.51) | KDM4EALDH1A1HPGDGAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601678-A2 | FUSED PYRROLE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050014754-A1 | Fused pyrrole compounds | SYNTA PHARMACEUTICALS CORP. | 2005-01-20 | — | — | US | disclosed |
| WO-2004082606-A2 | FUSED PYRROLE COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004082606-A2 | FUSED PYRROLE COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014754-A1 | Fused pyrrole compounds | PDE4A, PDE4B, IL4 | KDM4E 264/4885ALDH1A1 457/4885HPGD 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.